BriMindInvest Logo

HUM (HUM) Stock Analysis 2026

Healthcare
$391.06
as of 2026-08-26

BriMind AI Score

Proprietary
43
Neutral
Price CAGR
8.6%
1Y Return
+26.5%
Analyst Upside
+9.9%
Rev Growth
26.2%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

BriMind 1-Year Price Target

$528.02+35.0% potential
Bear Case
$301.04
Bull Case
$642.10
Model Confidence90%

BriMind AI combines DCF, momentum, and analyst consensus to project a 12-month price target.

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

HUM Revenue & Profitability Breakdown

This chart shows how HUM's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$145.68B
Cost of Revenue
-$125.79B
Gross Profit
$19.89B13.7% margin
Operating Expenses
-$14.84B
Operating Income
$5.05B3.5% margin
Tax & Other
-$3.77B
Net Income
$1.28B0.9% margin
Gross Margin
13.7%
Operating Margin
3.5%
Net Margin
0.9%

Key Financial Metrics

HUM trades at a trailing P/E of 35.84x, generates $1.94B in free cash flow, runs a debt/equity ratio of 76.48, and converts shareholder equity into profit at a 6.9% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$45.50B
P/E (Trailing)
35.84
P/E (Forward)
22.87
Revenue
$145.68B
Revenue Growth
26.2%
Earnings Growth
27.1%
Gross Margin
13.7%
Operating Margin
3.5%
Net Margin
0.9%
Return on Equity
6.9%
Return on Assets
3.9%
Free Cash Flow
$1.94B
Debt / Equity
76.48
Current Ratio
1.74
Quick Ratio
1.28
Beta
0.74
Dividend Yield
0.9%
Payout Ratio
33.5%
Book Value / Share
$160.00

Wall Street Analyst Consensus

Wall Street analysts covering HUM currently haven't converged on a clear consensus rating, with a mean 12-month price target of $416.43 (+6.5% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Mean Target$416.43+6.5% upside

Compare HUM with Peers

HUM vs MOHHumana vs Molina Healthcare — Medicare Advantage vs Med
CI vs HUMCigna vs Humana — Which Managed Care Stock Wins?

Unlock the Full HUM Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis